UK Biotech Start-up TC BioPharm Completes Clinical Manufacturing FacilityBy
TC BioPharm, a clinical-stage biopharmaceutical company based in Scotland, has completed its clinical manufacturing facility at Maxim Park, Glasgow. TC Biopharm has a cell-based product pipeline focused on treating cancer and severe viral infections. The company aims to commence Phase II/III clinical studies in melanoma patients in mid-2015. TCB's technology uses patients' own immune cells grown in culture to target cancer.
In March 2014, TC BioPharm announced a strategic collaboration with MEDINET, a Tokyo-listed immuno-cell therapy company, to develop a novel treatment for various different types of cancer. MEDINET is exclusively licensing its cell therapy technology to TC Biopharm for clinical development in the UK and Europe. This collaboration and subsequent commercialization is supported by Scottish Development International (SDI), the international arm of Scotland's enterprise agencies.
The facility consists of offices, two cleanrooms, quality control suites,and development laboratories. The total footprint is 5,000 square feet, of which 3,500 square feet is designed to support manufacture of clinical-grade product. Based in North Lanarkshire at the Eastern end of Glasgow's BioCorridor, the new cleanroom facility will require an investigational medicinal product license from the UK Medicines and Healthcare Products Regulatory Agency before clinical product can be made. The MHRA inspection of the facility is expected in November 2014.
Source: TC BioPharm